Aldeyra Therapeutics Inc. (ALDX)
5.30
-0.17 (-3.20%)
At close: Apr 02, 2025, 3:59 PM
5.01
-5.47%
After-hours: Apr 02, 2025, 05:33 PM EDT
Aldeyra Therapeutics Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | n/a | 262.78K | 258.71K | 264.18K | 56.22K | 96.31K | 71K | 37.85K | 35.79K | 18.78K | n/a | n/a | n/a | n/a |
| Gross Profit | n/a | -262.78K | -258.71K | -264.18K | -56.22K | -96.31K | -71K | -37.85K | -35.79K | -18.78K | n/a | n/a | n/a | n/a |
| Operating Income | -60,117B | -42.79M | -62.68M | -56.22M | -36.42M | -63.07M | -39.7M | -22.49M | -18.7M | -11.99M | -7.27M | -3.68M | -1.11M | -2.11M |
| Interest Income | 6,191.8B | 7.32M | 2.35M | 185.36K | 292.22K | 1.54M | 952.7K | 261.25K | 102.04K | 11.13K | 3.00 | 31.00 | 101.00 | 5K |
| Pretax Income | -55,851.4B | -37.54M | -62.02M | -57.78M | -38.03M | -62.14M | -38.89M | -22.34M | -18.7M | -12.09M | -5.19M | 13.06M | -23.07M | -2.38M |
| Net Income | -55,851.4B | -37.54M | -61.37M | -59.25M | -37.55M | -60.83M | -38.89M | -22.34M | -18.7M | -12.09M | -5.19M | 13.06M | -23.07M | -2.38M |
| Selling & General & Admin | 11,892.2B | 13.34M | 15.37M | 11.28M | 9.99M | 12.15M | 9.88M | 6.19M | 5.52M | 4.41M | 3.56M | 2.13M | 644.94K | 743.94K |
| Research & Development | 48,224.8B | 29.46M | 47.31M | 44.94M | 24.68M | 44.35M | 29.82M | 16.3M | 13.18M | 7.57M | 3.71M | 1.54M | 469.27K | 1.36M |
| Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 2.33M | 720.78K | -21.48M | 5.41K |
| Operating Expenses | 60,117B | 42.79M | 62.68M | 56.22M | 34.67M | 56.51M | 39.7M | 22.49M | 18.7M | 11.99M | 7.27M | 3.68M | 1.11M | 2.11M |
| Interest Expense | -1,926.2B | 2.07M | 1.69M | 1.74M | 1.9M | 603.85K | 146.79K | 113.45K | 105.51K | 112.31K | 244.17K | 159.32K | 342.01K | 279.93K |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | n/a | 42.79M | 62.68M | 56.22M | 34.67M | 56.51M | 39.7M | 22.49M | 18.7M | 11.99M | 7.27M | 3.68M | 1.11M | 2.11M |
| Income Tax | n/a | n/a | -655.35K | 1.48M | -479.26K | -1.31M | 952.7K | 223.4K | 66.25K | -7.65K | 243.1K | 159.29K | -21.14M | 285.34K |
| Shares Outstanding (Basic) | 59.48M | 58.94M | 58.41M | 54.04M | 33.97M | 27.11M | 21.69M | 15.92M | 11.35M | 8.63M | 3.82M | 327.37K | 4.04M | 327.37K |
| Shares Outstanding (Diluted) | 59.48M | 58.94M | 58.41M | 54.04M | 33.97M | 27.11M | 21.69M | 15.92M | 11.35M | 8.63M | 3.85M | 4.8M | 4.52M | 4.8M |
| EPS (Basic) | -938.92K | -0.64 | -1.05 | -1.1 | -1.11 | -2.24 | -1.79 | -1.4 | -1.65 | -1.4 | -1.36 | 39.90 | -5.72 | -7.26 |
| EPS (Diluted) | -938.92K | -0.64 | -1.05 | -1.1 | -1.11 | -2.24 | -1.79 | -1.4 | -1.65 | -1.4 | -1.35 | 2.72 | -5.1 | -0.5 |
| EBITDA | -60,117B | -35.21M | -60.07M | -55.77M | -36.07M | -61.44M | -38.68M | -22.19M | -18.56M | -11.96M | -4.94M | 13.22M | -22.73M | -2.1M |
| EBIT | -57,777.7B | -35.47M | -60.33M | -56.03M | -36.13M | -61.53M | -38.75M | -22.23M | -18.59M | -11.98M | -4.94M | 13.22M | -22.73M | -2.1M |
| Depreciation & Amortization | n/a | 262.78K | 258.71K | 264.18K | 56.22K | 96.31K | 71K | 37.85K | 35.79K | 18.78K | 1.07K | 31.00 | 3.74K | 1.59K |